Bristol-Myers Squibb (NYSE:BMY) – Investment analysts at William Blair reduced their FY2018 earnings per share estimates for shares of Bristol-Myers Squibb in a research note issued on Tuesday, April 17th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of $3.18 for the year, down from their previous estimate of $3.21. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Bristol-Myers Squibb’s Q4 2018 earnings at $0.76 EPS, Q1 2019 earnings at $0.83 EPS, Q2 2019 earnings at $0.85 EPS, Q3 2019 earnings at $0.88 EPS, Q4 2019 earnings at $0.90 EPS, FY2019 earnings at $3.46 EPS and FY2020 earnings at $4.11 EPS.
A number of other research firms have also commented on BMY. Citigroup set a $78.00 target price on Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Friday, February 16th. Jefferies Group set a $72.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, February 26th. TheStreet lowered Bristol-Myers Squibb from a “b” rating to a “c+” rating in a report on Thursday, March 8th. DZ Bank lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, February 28th. Finally, Argus reissued a “buy” rating and issued a $66.43 target price (down previously from $75.00) on shares of Bristol-Myers Squibb in a report on Wednesday, March 21st. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $64.51.
Bristol-Myers Squibb stock opened at $52.30 on Wednesday. The firm has a market capitalization of $88,290.09, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 1.41 and a beta of 0.96. Bristol-Myers Squibb has a 12 month low of $51.56 and a 12 month high of $70.05. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43.
Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.63 EPS.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Advisor Partners LLC lifted its position in Bristol-Myers Squibb by 6.9% during the third quarter. Advisor Partners LLC now owns 36,961 shares of the biopharmaceutical company’s stock valued at $2,356,000 after purchasing an additional 2,382 shares in the last quarter. Van ECK Associates Corp lifted its position in Bristol-Myers Squibb by 0.7% during the third quarter. Van ECK Associates Corp now owns 791,275 shares of the biopharmaceutical company’s stock valued at $50,436,000 after purchasing an additional 5,451 shares in the last quarter. Aperio Group LLC lifted its position in Bristol-Myers Squibb by 12.7% during the third quarter. Aperio Group LLC now owns 854,457 shares of the biopharmaceutical company’s stock valued at $54,463,000 after purchasing an additional 96,561 shares in the last quarter. D.A. Davidson & CO. lifted its position in Bristol-Myers Squibb by 8.6% during the third quarter. D.A. Davidson & CO. now owns 205,789 shares of the biopharmaceutical company’s stock valued at $13,117,000 after purchasing an additional 16,310 shares in the last quarter. Finally, First Interstate Bank lifted its position in Bristol-Myers Squibb by 6.3% during the third quarter. First Interstate Bank now owns 118,681 shares of the biopharmaceutical company’s stock valued at $7,565,000 after purchasing an additional 7,030 shares in the last quarter. Institutional investors own 71.51% of the company’s stock.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, April 5th. This represents a $1.60 annualized dividend and a yield of 3.06%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 53.16%.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/19/fy2018-eps-estimates-for-bristol-myers-squibb-decreased-by-william-blair-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.